Ventures Viii Lp Avalon Ven... Net Worth

The estimated Net Worth of Ventures Viii Lp Avalon Ven... is at least $62.8 Thousand dollars as of 18 August 2014. Ventures Ven owns over 109,375 units of Otonomy Inc stock worth over $62,753 and over the last 10 years Ventures sold OTIC stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures Ven OTIC stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Otonomy Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Ventures bought 109,375 units of OTIC stock worth $1,750,000 on 18 August 2014.

The largest trade Ventures's ever made was buying 109,375 units of Otonomy Inc stock on 18 August 2014 worth over $1,750,000. On average, Ventures trades about 109,375 units every 0 days since 2014. As of 18 August 2014 Ventures still owns at least 814,973 units of Otonomy Inc stock.

You can see the complete history of Ventures Ven stock trades at the bottom of the page.

What's Ventures Ven's mailing address?

Ventures's mailing address filed with the SEC is 1134 KLINE STREET1134 KLINE STREET, , LA JOLLALA JOLLA, CACA, 9203792037.

Insiders trading at Otonomy Inc

Over the last 10 years, insiders at Otonomy Inc have traded over $30,282,796 worth of Otonomy Inc stock and bought 755,065 units worth $12,114,945 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Holdings A/S Novo, and Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of $7,317. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth $4,224.

What does Otonomy Inc do?

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.

Complete history of Ventures Ven stock trades at Otonomy Inc

Otonomy Inc executives and stock owners

Otonomy Inc executives and other stock owners filed with the SEC include:

• David Weber,
  President, Chief Executive Officer, Director
• Dr. David Allen Weber,
  Pres, CEO & Director
• Paul Cayer,
  Chief Financial and Business Officer
• Robert Savel,
  Chief Technical Officer
• Paul E. Cayer,
  Chief Financial & Bus. Officer
• Robert Michael Savel II,
  Chief Technical Officer
• Jay Lichter,
  Independent Chairman of the Board
• Vickie Capps,
  Independent Director
• Iain McGill,
  Independent Director
• James Breitmeyer,
  Independent Director
• Theodore Schroeder,
  Independent Director
• Dr. Jay B. Lichter Ph.D.,
  Co-Founder & Independent Chairman
• Ciara Kennedy,
  Independent Director
• James Branch CPA,
  VP of Fin. & Controller
• David Skarinsky,
  Sr. VP of Clinical
• Breianna Bowen,
  VP of HR
• Fabrice Piu Ph.D.,
  Sr. VP of Preclinical Devel.
• Barbara M. Finn,
  Sr. VP of Regulatory Affairs & Quality Assurance
• Dr. Alan Charles Foster Ph.D.,
  Chief Scientific Officer
• Julie D. Burgess,
  VP of Fin. & Admin.
• Dr. Rick Adam Friedman M.D., Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Dr. Allen F. Ryan Ph.D.,
  Co-Founder and Member of the Advisory Panel
• Katherine Mary Bishop,
  Chief Scientific Officer
• Eric J Loumeau,
  GC & Chief Compliance Officer
• Carl Le Bel,
  Chief Scientific Officer
• Heather Preston,
  Director
• George J Morrow,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Chau Quang Khuong,
  Director
• Anthony J Yost,
  Chief Commercial Officer
• Dean Hakanson,
  Chief Medical Officer
• John P Mckearn,
  Director
• Partners Viii, L.P.Blair Ja...,
  
• Ventures Viii Lp Avalon Ven...,
  
• Holdings A/S Novo,
  10% owner
• Group Holdings (Sbs) Adviso...,
  
• Viii Associates, L.P.Domain...,
  
• Alan Charles Foster,
  Chief Scientific Officer
• Brian H Dovey,
  Director
• Jill Marie Broadfoot,
  Director